Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Predictors of Early Relapse After Cilta-Cel in R/R MM

Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Predictors of Early Relapse After Cilta-Cel in R/R MM

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

ID 93 – Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Studies/trials discussed:

ID 93 – Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma
Tagged